Stifel’s Picks In Biotech: Stocks With Catalysts Or Compelling Valuations

To say that the biotech sector has been volatile lately would be an understatement. But many industry watchers are still trying to decide whether or not the fall is overdone, or just the start greater pain as the bubble pops. Stifel Nicolaus analyst Stephen Willey comes down in the former camp. In a note out [...]